Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Su-6668. SUGEN.

D Fabbro1, P W Manley

  • 1Novartis Pharma AG, Department of Oncology, Basel, Switzerland. doriano.fabbro@pharma.novartis.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Midostaurin: a magic bullet that blocks mast cell expansion and activation.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.

Leukemia·2015
Same author

Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.

Oncogene·2015
Same author

The Concise Guide to PHARMACOLOGY 2013/14: overview.

British journal of pharmacology·2014
Same author

Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.

Oncogene·2013
Same author

EGFR expression is linked to osteopontin and Nf-κB signaling in clear cell renal cell carcinoma.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2012
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

SU-6668, a novel tyrosine kinase inhibitor, is undergoing Phase I trials for advanced cancers. Early data is assessing oral administration safety and toxicity in fed and fasting patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • SUGEN is developing SU-6668, a tyrosine kinase inhibitor targeting three growth factor receptors.
  • SU-6668 is being investigated for the potential treatment of various cancers.

Purpose of the Study:

  • To determine the toxicities of SU-6668 in patients with advanced malignancies.
  • To evaluate SU-6668 administered orally to fed and fasting patients.

Main Methods:

  • Phase I dose-escalation study involving oral administration of SU-6668.
  • Doses ranged from 100 to 2400 mg/m2, once or twice daily.
  • 74 patients were enrolled in the study at UCLA.

Main Results:

  • Accrual is ongoing to define toxicities at doses > 200 mg/m2 twice-daily.

Related Experiment Videos

  • An earlier IV formulation trial was halted due to formulation issues and observed toxicities like nausea and vomiting.

    • Conclusions:

    • Phase I trials are ongoing to establish the safety profile of orally administered SU-6668.
    • Further studies are needed to define maximum tolerated doses and potential therapeutic benefits.